Cytek Biosciences appoints Chris Williams as COO, effective Oct. 31, 2022

Cytek Biosciences, Inc.

Chris Williams appointed COO, reporting to CEO Wenbin Jiang; focused on scaling global operations.
Annual base salary of $395,000; target bonus 50% of base; $100,000 sign-on cash bonus (clawback within 12 months).
Equity grants of $500,000, split 50% stock options and 50% RSUs, vesting over four years.
Williams previously VP at Thermo Fisher Scientific and Bayer Pharmaceuticals.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Chris Williams

Chief Operating Officer

CTKB · Cytek Biosciences, Inc.

Effective: 2022-10-31
Filed: November 1, 2022, 7:59 PM ET

the Board of Directors (the “Board”) of Cytek Biosciences, Inc. (the “Company”) announced the appointment of Chris Williams as the Company’s Chief Operating Officer, effective October 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Chris Williams was appointed as Chief Operating Officer at Cytek Biosciences, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

the Board of Directors (the “Board”) of Cytek Biosciences, Inc. (the “Company”) announced the appointment of Chris Williams as the Company’s Chief Operating Officer, effective October 31, 2022.

View on SEC.gov

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-275058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.